Coverage Initiated: October 2004

BioMarin (BMRN) leverages its expertise with enzyme therapies to pursue a number of orphan indications for serious childhood diseases. The company pursues orphan diseases in which the biological mechanisms are well understood but lack adequate treatment. BioMarin is a fully integrated biopharma company from R&D, to in-house manufacturing and sales force in the USA, Europe, and other selected countries like Brazil.

BioMarin has been a top pick by the BSR Research Team for a number of years. It has been a solid performer in the BSR Model Portfolio. BioMarin continues to expand its pipeline while strengthening profitability.

A complete listing of our research on BioMarin Therapeutics is available by clicking here.